Development The Potentiality of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) From Mycelia Extract of Indonesia's Ganoderma Lucidum as Adjuvant Therapy in Patients With Cardiometabolic Syndrome

• Status: Enrolling by invitation
• Trial end date: 2022-01-06
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to determine the role and efficacy of β-1,3/1,6-D-Glucan (Polysaccharide Peptide) from mycelia extract of Indonesia's Ganoderma lucidum as an antioxidant and anti-inflammatory agent on cardiometabolic syndrome

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Brawijaya
• Collaborator: PT. Sahabat Lingkungan Hidup

Criteria

Inclusion Criteria:

• Age more or same than 18 years old

• Defined as metabolic syndrome patients based on NCEP-ATP III Criteria with modified of obesity classification (waist measurement) for Asian population

• Agreed to participate in this study

Exclusion Criteria:

• Allergic to Ganoderma lucidum

• Pregnant woman

• Participate in another drug or medical device study

• Waiting for an organ transplantation or have undergone a transplant

• Cancer patients who undergoing a chemotherapy or radiotherapy

• People with organ failure

• Could not be randomized and participate in this study by clinical judgement